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Disease subtypingPatient interactions with health care providers result in entries to electronic health records (EHRs). EHRs
were built for clinical and billing purposes but contain many data points about an individual. Mining
these records provides opportunities to extract electronic phenotypes, which can be paired with genetic
data to identify genes underlying common human diseases. This task remains challenging: high quality
phenotyping is costly and requires physician review; many fields in the records are sparsely filled; and
our definitions of diseases are continuing to improve over time. Here we develop and evaluate a semi-
supervised learning method for EHR phenotype extraction using denoising autoencoders for phenotype
stratification. By combining denoising autoencoders with random forests we find classification improve-
ments across multiple simulation models and improved survival prediction in ALS clinical trial data. This
is particularly evident in cases where only a small number of patients have high quality phenotypes, a
common scenario in EHR-based research. Denoising autoencoders perform dimensionality reduction
enabling visualization and clustering for the discovery of new subtypes of disease. This method repre-
sents a promising approach to clarify disease subtypes and improve genotype-phenotype association
studies that leverage EHRs.
 2016 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Biomedical research often considers diseases as fixed pheno-
types, but many have evolving definitions and are difficult to clas-
sify. The electronic health record (EHR) is a popular source for
electronic phenotyping to augment traditional genetic association
studies, but there is a relative scarcity of research quality anno-
tated patients [1]. Electronic phenotyping relies on either codes
designed for billing or time intensive manual clinician review. Thisis an ideal environment for semi-supervised algorithms, perform-
ing unsupervised learning on many patients followed by super-
vised learning on a smaller, annotated, subset. Denoising
autoencoders (DAs) are a powerful tool to perform unsupervised
learning [2]. DAs are a type of artificial neural network trained to
reconstruct an original input from an intentionally corrupted
input. Through this training they learn higher-level representa-
tions modeling the structure of the underlying data. We sought
to determine whether applying DAs to the EHR could reduce the
number of annotated patients required, construct non-billing code
based phenotypes and elucidate disease subtypes for fine-tuned
genetic association.
The United States federal government mandated meaningful
use of EHRs by 2014 to improve patient care quality, secure and
communicate patient information, and clarify patient billing
[3,4]. Despite not being designed specifically for research, EHRs
have already proven an effective source of phenotypes in genetic
association studies [5,6]. Initially, phenotypes were hand designed
based on manual clinician review of patient records. These studies
were limited by the time and cost inherent in manual review [7,8],
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training, the trained DA’s hidden layer can be used as input to a tra-
ditional classifier to create a semi-supervised learner. This allows
the DA to learn from all samples, even those without labels, and
requires only a small subset to be annotated. Today, phenome-
wide association studies (PheWAS) are the most prevalent example
of EHR phenotyping, proving particularly effective at identifying
pleiotropic genetic variants [9]. PheWASs often use algorithms
based on the International Classification of Disease (ICD) codes to
construct a phenotype. This coding system was designed for bill-
ing, not to capture research phenotypes. DA constructed features
are combinations of many components of clinical data and may
provide a more holistic view of a patient than billing codes alone.
Through extensive study, disease diagnoses can become more
precise over time [10–14]. Cancers, for example, were historically
typed by occurrence location and the efficacy of different treat-
ments. As the mechanisms of cancer are better understood, they
are further categorized by their physiological nature. The progres-
sion of subtypes in lung cancer illustrates this increased under-
standing over time [10]. Beginning with a single diagnosis based
on occurrence in the lung, lung cancer has been divided into doz-
ens of subtypes over several decades based on histological analysis,
and genetic markers [11–14]. The unsupervised nature of DAs
means that even if the definitions of a disease change, they would
not need to be retrained. The ability to identify more homogenous
phenotypes showed increased genotype to phenotype linkage in
schizophrenia, bipolar disease [15], and Rett Syndrome [16–19].
Furthermore, type 2 diabetes subtypes have been discovered using
topological analysis of EHR patient similarity [20]. The dimension-
ality reduction possible with a DA makes clustering and visualiza-
tion more feasible. Subtyping exposes disease heterogeneity and
may contribute to additional physiological understanding.
Previous work in semi-supervised learning of the EHR relies on
closed source commercial software [20], and natural language pro-
cessing of free text fields to match clinical diagnosis [21,22]. We
are not aware of any previous work performing semi-supervised
classification and clustering from quantitative structured patient
data.
We evaluate DAs for phenotype construction using four simula-
tion models of EHR data for complex phenotypes, modify DAs to
effectively handle missingness in data and use the DA to create
cluster visualizations that can aid in the discovery of subtypes of
complex diseases. We apply these methods to predict ALS patient
survival and to visualize ALS patient clusters. ALS is a progressive
neurodegenerative disorder, which attacks the neurons responsi-
ble for controlling muscle function [23]. ALS patients typically
die within 3–5 years, but some patients can survive more than
10 years, the disease is considered clinically heterogeneous and
predicting the rate of progression can be challenging [24].2. Methods
We developed an approach, entitled ‘‘Denoising Autoencoders
for Phenotype Stratification (DAPS),” that constructs phenotypes
through unsupervised learning. This generalized phenotype con-
struction can be used to classify whether patients have a particular
disease or to search for disease subtypes in patient populations. To
evaluate DAPS, we created a simulation framework with multiple
hidden factors influencing potentially overlapping observed vari-
ables. We evaluated the reduced DA models against feature-
complete representations with popular supervised learning algo-
rithms. These evaluations covered both complete datasets, as well
as the more realistic cases of incompletely labeled and missing
data. We developed a technique that uses the reduced feature-
space of the DA to visualize potential subtypes. Finally, we evaluateDAs ability to predict ALS patient survival in both classification and
clustering tasks. Each of these is fully described below and full
parameters included in sweeps are available in the supplementary
materials.
Source code to reproduce each analysis is included in our repos-
itory (https://github.com/greenelab/DAPS) [25] and is provided
under a permissive open source license (3-clause BSD). A docker
build is included with the repository to provide a common envi-
ronment to easily reproduce results without installing dependen-
cies [26]. In addition, Shippable, a continuous integration
platform, is used to reanalyze results in a clean environment and
generate figures after each commit [27].
2.1. Unsupervised training with denoising autoencoders
DAs were initially introduced as a component in constructing
the deep networks used in deep learning [28]. Deep learning algo-
rithms have become the dominant performers in many domains
including image recognition, speech recognition and natural lan-
guage processing [29–34]. Recently they have also been used to
solve biological problems including tumor classification, predicting
chromatin structure and protein binding [2,35,36]. DAs showed
strong performance early in the deep learning revolution but have
been surpassed in most domains by convolutional neural networks
or recurrent neural networks [28]. While these complex deep net-
works have surpassed the performance of DAs in these areas, they
rely on strictly structured relationships such as the relative posi-
tions of pixels within an image [31,37]. This structure is unlikely
to exist in the EHR. In addition, complex deep networks are noto-
riously hard to interpret. DAs are easily generalizable, benefit from
both linear and nonlinear correlation structure in the data, and
contain accessible, interpretable, internal nodes [2]. Oftentimes
the hidden layer is a ‘‘bottle-neck”, a much smaller size than the
input layer, in order to force the autoencoder to learn the most
important patterns in the data [37].
We used the Theano library [38,39] to construct a DA consisting
of three layers, an input layer x, a single hidden layer y, and a
reconstructed layer z [28] (Fig. 1A). Noise was added to the input
layer through a stochastic corruption process, which masks 20%
of the input values, selected at random, to zero.
The hidden layer y was calculated by multiplying the input
layer by a weight vector W, adding a bias vector b and computing
the sigmoid (Formula 1). The reconstructed layer z was similarly
computed using tied weights, the transpose of W and b (Formula
2). The cost function is the cross-entropy of the reconstruction, a
measure of distance between the reconstructed layer and the input
layer (Formula 3).
y ¼ sðWxþ bÞ ðFormula1Þ
z ¼ s W 0yþ b0  ðFormula2Þ
cost ¼ 
Xd
k¼1
xk logðzkÞ þ ð1 xkÞ logð1 zkÞ½  ðFormula3Þ
Stochastic gradient descent was performed for 1000 training
epochs, at a learning rate of 0.1. Hidden layers of two, four, eight
and sixteen hidden nodes were included in the parameter sweep
with a 20% input corruption level. Vincent et al. [28] provide a
through explanation of training for DAs without missing data.
In the event of missing data, the cost calculation was modified
to exclude missing data from contributing to the reconstruction
cost. A missingness vector m was created for each input vector,
with a value of 1 where the data is present and 0 when the data
is missing. Both the input sample x and reconstruction zwere mul-
tiplied by m and the cross entropy error was divided by the sum of
Fig. 1. (A) Network diagram of DAs used for unsupervised pre-training. Input data is intentionally corrupted and then weights and biases are learned to minimize
reconstruction cost when mapping the data to a hidden layer and back to a reconstructed layer. (B) Supervised classification occurs using the pre-trained DA hidden nodes as
input to a traditional classifier. (C) Simulation model with example cases and controls under each rule set.
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per feature present (Formula 4). This allowed the DA to learn the
structure of the data from present features rather than imputation.
cost ¼ 
Xd
k¼1
xk logðzkÞmk þ ð1 xkÞ logð1 zkÞmk½ =countðmÞ
ðFormula4Þ
2.2. Supervised denoising autoencoder classifier
To convert the DA to a supervised classifier, we first trained the
DA in an unsupervised fashion (pre-training) (Fig. 1A). We then
applied a variety of traditional machine learning classifiers includ-
ing, decision trees, random forests, logistic regression, nearest
neighbors and support vector machines to the pre-trained unsu-
pervised hidden layer values, y, of the DA (Fig. 1B). Random forests
applied to DA hidden nodes (DA + RF) were shown for all compar-
isons. Predictive performance was measured by comparing the
AUROC using stratified 10-fold cross validation. The Scikit-learn
library was used for the traditional classifiers [40]. The Support
Vector Machine uses a radial basis function kernel, with a penalty
parameter of 1. The nearest neighbors classifier uses a k-value of 5
and the random forest uses 10 estimators. These parameters
achieved optimal performance in a preliminary parameter sweep.
2.3. Simulation framework
We designed four simulation models to evaluate algorithmic
performance. These simulations were not designed to perfectly
recapitulate EHR data. Instead they are designed to capture a vari-
ety of complexity in order to identify algorithmic strengths and
weaknesses with known underlying models.
To simulate patients, first clinical observations were generated
by first drawing random samples from a normal distribution. Next
hidden input effects were generated in accordance with one of foursimulation models. When turned on these hidden input effects
shift 1 to N observed clinical variables with replacement (Fig. 1C).
Shifted clinical features were chosen at random, but consistent for
all patients. Case-control status was determined by rules applied to
the hidden input effects, where 1 represents the effect being on
and 0 represents the effect being off. Next, a confounding system-
atic bias was added to a random subset (33%) of the patients as a
source of additional noise to simulate the variance accompanying
data created by physicians, labs, hospitals or other spurious effects.
There are four models defining hidden input effect rules to
determine case-control status:
1. All together/all relevant. Individuals have the same value (0 or
1) for all hidden input effects. Controls have all hidden effects
set to 0. Cases have all hidden effects set to 1. A model capturing
any hidden input will be able to predict case/control status in
this scenario. This is a test of whether each method can recog-
nize any of the hidden effects.
2. All independent /single effect relevant. Individuals have 0 to N
(specified per simulation) hidden input effects chosen at ran-
dom. One arbitrary effect (the last one) is used to determine
case-control status. In controls, this is 0. In cases, this is 1. A
model capturing the relevant hidden input will be able to pre-
dict case/control status in this scenario. This is a test of whether
each method can recognize the important hidden effect when
there are multiple shifted distributions.
3. All independent/percentage based. Individuals have 0 to N
(specified per simulation) of hidden input effects chosen at ran-
dom set to 1. The percentage of hidden input effects on repre-
sents the probability of the patient being a case. A model
capturing more hidden effects will be able to more accurately
predict case/control in this scenario. This is a test of whether
each method can perform effectively without a hard-rule based
model, and could represent a disease with incomplete
penetrance.
Table 1
Simulation model 1 parameter sweep specifications.
Parameter Values
Observed variables 50, 100, 200, 400
Effect magnitude (variance) 1, 2, 4
Hidden input effects 1, 2, 4, 8, 16
Effected observed variables per hidden input
effect
5, 10
Unlabeled patients 10,000
Labeled patients 100, 200, 500, 1000, 2000
Systematic bias 0.1 applied to 0.33 of
patients
DA hidden nodes 1, 2, 4, 8
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(specified per simulation) of hidden inputs chosen at random
set to 1. The sum of hidden effects determines case-control sta-
tus (cases are even, controls are odd). A model must capture all
hidden effects to successfully predict case/control in this sce-
nario. This is a test to identify the complexity limitations of each
of the methods.
Simulation model 3 could reflect a disease with incomplete
penetrance. The probabilistic manner of this simulation means that
the optimum binary classifier will have an expected accuracy lim-
ited by the role of stochasticity in the model. The amount of
stochasticity is a function of the number of hidden effects. In this
model, case control odds were equal to the percentage of hidden
input effects on. If there are 4 hidden input effects and 2 are on,
the patient has a 50% chance of being a case and a 50% chance of
being a control. A binary classifier can perfectly model this simula-
tion and still have error due to the probabilistic nature. The maxi-
mum expected accuracy was calculated from a binomial
distribution multiplied by the minority percentage as the best a
binary classifier could do is choose the more likely class. For exam-
ple, in the case of 4 hidden effects the maximum expected accuracy
is 68.75%.
An example of a hypothetical condition a hidden input effect
could represent is the familial hypercholesterolemia genotype.
For a patient with the familial hypercholesterolemia genotype,
the simulated clinical observations could represent increases in
levels of total and low-density lipoprotein cholesterol, the deposi-
tion of cholesterol in extravascular tissues, corneal arcus and ele-
vated triglyceride levels [41]. Some factors such as elevated
triglyceride levels are not solely the result of the genetic predispo-
sition and are related to environmental factors. Hypothetically
additional hidden input effects on the same observed variable
would represent these other factors. Because our goal is to evaluate
methods for their ability to broadly capture these types of patterns,
we generate randomized relationships between hidden and
observed variables. This avoids overfitting our evaluation to speci-
fic phenotypes.
2.4. Supervised classification comparison
If successfully trained, the hidden layer of a DA, y, captures the
first n factors of variation in the data, where n is the number of
nodes in the hidden layer. To test whether the DA constructed use-
ful features by learning the main factors of variation in the data we
used the trained hidden layer as an input to a shallow classifier.
To do this, we first completed unsupervised pre-training of the
DA with all of the simulated samples. The hidden layer values, y,
were calculated for all samples using the trained DA without any
corruption and fed in as the features to a random forest to form
a supervised classifier.
Classification performance between DAs plus random forests
(DA + RF) were compared against decision trees, random forests,
nearest neighbors and support vector machines in a parameter
sweep under each model (Table 1). Additional model parameters
included in sweeps are included in the supplementary materials.
All traditional classifiers were implemented with Scikit-learn
[40]. Classification performance was compared using the AUROC
with 10-fold cross validation across 10 independent replicates for
each set of parameters.
2.5. Semi-supervised classification comparison
The supervised classification comparison was repeated but with
additional patients simulated and utilized during the unsupervised
pre-training of the DA. The additional patients were simulated atthe same 50% case, 50% control ratio but their labels were dis-
carded after simulation. These additional patients were mixed with
the original labeled patients and included in the unsupervised pre-
training of the DA. The unlabeled samples were then discarded and
the DA + RF was then provided the same, labeled, patient groups as
the traditional classifiers. The labeled patient samples were run
through the trained DA in the same manner as the unsupervised
pre-training but without any corruption added to the data. The
DA + RF and traditional classifiers were evaluated in a parameter
sweep under each model using 10-fold cross validation.
2.6. Missing data comparison
The semi-supervised classification comparison was repeated
five times with, 0%, 10%, 20%, 30% and 40% of the data missing.
Missing data was added at random per sample, depending on the
specified percentage missing.
Throughout these trials, the cost calculation was modified to
exclude missing data from the cost and allow the DA to learn with-
out imputing values (Formula 4). The traditional classifiers were
trained using mean imputation for missing data. Mean imputation
is particularly well suited for the simulation models because the
observations were drawn from normal distributions, potentially
giving an advantage to the non-DA algorithms that would not be
available in many real datasets.
As in the semi-supervised classification comparison trial, the
DA + RF and traditional classifiers were evaluated under each
model using 10-fold cross validation.
2.7. Clustering and visualization
To interpret and visualize results, patient populations were
clustered using principal components analysis (PCA) and t-
Stochastic Neighbor Embedding (t-SNE) of the trained DA’s hidden
nodes [42,43]. PCA and t-SNE were implemented with the Sci-kit
learn library [40].
Ten thousand patients (5000 cases, 5000 controls) with four
hidden effects were simulated under model 1. PCA followed by t-
SNE was performed initially on the raw input for comparison and
then on the hidden nodes of the DA after every 10 training epochs.
To test the ability to identify subtypes, we simulated 15,000
patients, 5000 cases under model 1, 5000 cases under model 2,
and 5000 controls. Input observations were compared to two, three
and four-node DAs using PCA followed by t-SNE.
2.8. ALS survival analysis
Data used in the ALS Survival portion of this article were
obtained from the Pooled Resource Open-Access ALS Clinical Trials
(PRO-ACT) Database. In 2011, Prize4Life, in collaboration with the
Northeast ALS Consortium, and with funding from the ALS Therapy
Alliance, formed the Pooled Resource Open-Access ALS Clinical
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Database has been volunteered by PRO-ACT Consortium members.
The PRO-ACT dataset includes 23 clinical trials covering 10,723
patients. We limit our survival analysis to the 3398 patients with
known death information, but perform unsupervised pre-training
of the DA with all 10,723 patients.
Patient data includes quantitative features consisting of demo-
graphic information, diagnosis history, family history, treatment
history, vital sign readings, concomitant medications and labora-
tory tests. Categorical variables were converted to one-hot encod-
ing. Repeated or temporal measurements were encoded as the
mean, minimum, maximum, count, standard deviation and slope
across each repeat. Measurement scales were standardized and
input features were normalized to be between 0 and 1. No imputa-
tion was performed on the input to the DA; K-nearest neighbors
imputation (K = 15) was performed for the raw comparison. This
preprocessing resulted in an input layer of 6812 numerical features
per patient.
Patient survival was predicted as the number of days from dis-
ease onset. Random Forest Regression using Scikit-learn with 1000
estimators was performed on the raw data and the hidden layer of
a 250 node DA trained for 1000 epochs. Performance was evaluated
using 10-fold cross validation. Cluster analysis using t-SNE was
compared between PCA (2, 4, 8, and 16 components) on the raw
input with the hidden layer of the DA.Fig. 2. Case vs. control clustering via principal components analysis and t-distributed sto
in yellow, cases are shown in red. (A) Raw input. (B) 0 training epochs. (C) 10 training epo
interpretation of the references to color in this figure legend, the reader is referred to th3. Results
3.1. Case-control DA training visualization
We trained a DA and visualized the training process using PCA
and t-SNE. These visualization techniques offer intuition and the
ability to examine the sub-clusters. Given 5000 cases and 5000
controls under simulation model 1, PCA and t-SNE alone did not
yield defined clusters (Fig. 2A). Fig. 2B–F shows the separation of
cases from controls as the DA is trained. One thousand epochs of
training via stochastic gradient descent were found to be sufficient
for the convergence of reconstruction cost and stabilization of visu-
alizations within simulated data (Fig. 2E and F, Supplemental
Fig. 1).
3.2. Fully supervised comparison
To examine the ability of DAs to learn the structure of the data
we compare the predictive ability of classification algorithms
applied to the DA constructed through unsupervised training. Ran-
dom forests demonstrated a strong balance of performance and
stability, and were used for all comparisons (Supplemental
Fig. 2). We then compare the DA plus a random forest classifier
(DA + RF) to the top performing classifiers on raw input data
(Table 2).chastic neighbor embedding throughout the training of the DA. Controls are shown
chs. (D) 100 training epochs. (E) 1000 training epochs F.) 10,000 training epochs. (For
e web version of this article.)
Table 2
Mean receiver operating curve area under curve by method under simulation model 1. (10 replicate, 10-fold cross validation.)
Patients DA + RF Random forest Support vector machine Decision tree Nearest neighbors
100 0.618 0.653 0.504 0.599 0.635
200 0.637 0.610 0.449 0.589 0.608
500 0.677 0.690 0.663 0.617 0.642
1000 0.774 0.717 0.776 0.634 0.651
2000 0.755 0.736 0.862 0.643 0.658
Mean 0.692 0.681 0.651 0.616 0.639
B.K. Beaulieu-Jones, C.S. Greene / Journal of Biomedical Informatics 64 (2016) 168–178 173Key trends emerged under each model; with few patients SVMs
had AUCs indistinguishable from those expected from a random
classifier. As one would expect, SVMs were top performers at when
the number of patients was high. Random forest classification per-
formance scaled steadily with patient count. The DA + RF per-
formed similarly to the random forest, showing that a 2-node DA
is able to capture at least one of the input hidden effects. Capturing
any signal is sufficient to accurately classify simulation model 1.
3.3. Semi-supervised comparison
The full potential of the DA + RF is reflected in semi-supervised
parameter sweep comparison for simulation model 1 (Fig. 3A).
Each set of parameters was evaluated with 10 replicates and 10-
fold cross validation for each replicate. With sufficient unlabeled
examples, the DA method’s performance is high, even with very
few labeled examples. Because of the extreme feature reduction,
the traditional classifier on top of the DA is able to reach its learn-
ing capacity with very few labeled patients (Fig. 3A). Efficient
learning from labeled examples is critical in practical use cases
because there are often few well-annotated cases due to the
expense of clinician manual review. The 2-node DA plus random
forest also showed strong performance in relation to an SVM when
there were many observed clinical variables (Supp. Fig. 3) and
when there were many hidden effects. The SVM again showed
the highest performance at very high numbers (1000 or more) of
labeled patients. The advantages of semi-supervised learning
diminish as the number of labeled patients gets closer to theFig. 3. Classification AUC in relation to the number of labeled patients under simulation
Forest, SVM – Support Vector Machine). Unsupervised pre-training of the 2-node DA w
median. Whiskers extend 1.5 times past the low and high quartiles. Points outside this r
choice expected performance (0.5).number of total patients. In addition, at high patient counts, a DA
with more than 2 hidden nodes is required to capture the structure
of the data with higher resolution.
These patterns repeat across the other simulation models, with
more complex models requiring more hidden nodes to adequately
model the structure of the data. In simulation model 2 (Fig. 4A),
both 4 and 8 node DAs outperform the 2-node DA. Under Model
3, the 4-node DA is the strongest performing, with median perfor-
mance 5% better than the next best traditional classifier. The 4-
node DA’s median 95% confidence interval was above any of the
compared methods. Model 4 (Fig. 4C and D) was the most difficult
to classify as the classifier had to capture all of the hidden effects to
be accurate. In several cases, no classifier did better than the
expected performance of a random classifier. In fact, the SVM’s
average AUC over the entire sweep was statistically indistinguish-
able from random performance. As expected, the 2-node performs
worse than the 4 and 8-node DAs on model 4. The 2-node DA lacks
sufficient dimensionality to capture more than 4 hidden input
effects.
Clinical records often have empty fields, so algorithms must be
robust to missing data. We evaluated the DA’s robustness in this
situation. The DA is robust to missing data maintaining near-max
classification performance across the missingness proportions
tested (Supp. Fig. 4). For these simulation models, the mean impu-
tation used for non-DA approaches is an ideal strategy. DAs and
SVMs show consistent performance even as the percent of data
missing increases, suggesting that the DA is at least as robust as
the ideal imputation method.model 1 (RF – Random Forest, NN – Nearest Neighbors, DA – 2-node DA + Random
as performed with 10,000 patients. Notch indicates 95% confidence interval for the
ange are denoted as dots and represent outliers. Gray dashed line indicates random
Fig. 4. Classification accuracy comparisons for models 2–4. Notch indicates 95% confidence interval for the median. Whiskers extend 1.5 times past the low and high
quartiles. Gray dashed line indicates random choice expected performance (50%). (A) Classification Accuracy of model 2 (1, 2, 4 and 8 effects). (B) Classification AUC
normalized to simulation model 2 expected max predictive accuracy (1, 2, 4 and 8 effects). (C) Classification AUC of model 4 (1, 2, 4 and 8 effects). (D) Classification AUC of
model 4 (parameter sweep results for 1, 2, 4 and 8 effects using only the parameter sets with 2000 labeled patients).
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We evaluated the DAPS’ ability to cluster patients for subtype
identification. To perform this analysis, we simulated 5000 cases
from each of two different models (1 and 2) to represent a disease
with two subtypes. An additional 5000 controls were simulated.
We then visualized the DA constructed from this set of patients
using PCA followed by t-SNE. In the input data, the subtypes are
relatively overlapping (Fig. 5A). A DA with two nodes was alsounable to separate this number of subtypes (Fig. 5B). Visualizations
constructed from DAs with three (Fig. 5C) or four (Fig. 5D) nodes
were able to effectively separate both subtypes of cases from each
other and from controls.
3.5. ALS survival analysis
We evaluated the DAPS’ ability to quantitatively predict ALS
patient survival (Fig. 6A) with ten-fold cross validation. Both
Fig. 5. Case vs. control clustering via principal components analysis and t-distributed stochastic neighbor embedding after training the DA for controls and cases generated
from a combination of models 1 and 2. Controls are shown in yellow, subtype 1 (model 1) is shown in red, subtype 2 (model 2) is shown in blue. (A) Raw input. (B) 1000
training epochs with 2 hidden nodes. (C) 1000 training epochs with 3 hidden nodes. (D) 1000 training epochs with 4 hidden nodes. (For interpretation of the references to
color in this figure legend, the reader is referred to the web version of this article.)
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pare predictions between the raw imputed data and the hidden
layer of a 250 node DA.
In order to visualize the basis for improved prediction, we per-
formed t-SNE clustering to compare PCA with the hidden layer of
the DA (Fig. 7A and B, Supp. Fig. 7). The visualization constructed
from the hidden layer of the DA shows space defined by the DA
separated several clear clusters with low patient survival as well
as a more heterogeneous cluster with longer survival. PCA applied
to the raw input produced some patterns but did not produce any
clear clustering by survival.
4. Discussion
In this study, we presented a semi-supervised learning
approach using DAs to model patients in the EHR. The benefits of
the method presented in this work are; (1) It is relatively inexpen-
sive to perform analysis on large amounts of unlabeled EHR data;(2) it is expensive to have data labeled at a research quality by a
clinician; (3) the DA + RF has strong performance when there are
many unlabeled samples and few labeled samples.
Competitive supervised classification accuracy with a large
degree of feature reduction indicates the DA successfully learned
the structure of the high-dimensional EHR data. DAs are particu-
larly well suited to the EHR because their unsupervised nature
allows the formation of a semi-supervised classifier and the ability
to utilize large un-annotated patient populations to improve clas-
sification accuracy. The dimensionality reduction of DAs allows
clustering of the reduced feature set for the visualization and
determination of subtypes. These clusters may reveal disease sub-
types, fine-tuned targets for genotype-phenotype association. The
DA models are easily de-constructible because they use a simple
model for the traditional classifier with transparent node composi-
tions that can be traced back to inputs. In addition, our method
proposes a straightforward modification to the DA to enable it to
process missing data without imputation.
Fig. 6. Ten-fold cross validation survival prediction quantification. Mean absolute
error in days. Notch indicates 95% confidence interval for the median. Whiskers
extend 1.5 times past the low and high quartiles. Points outside this range are
denoted as dots and represent outliers.
176 B.K. Beaulieu-Jones, C.S. Greene / Journal of Biomedical Informatics 64 (2016) 168–178PheWASs are a powerful tool to leverage the vast clinical data
contained in the electronic health record but currently suffer from
the reliance on billing codes or manual clinician annotation. Denny
et al. [1] call out the need for increased accuracy in phenotypeFig. 7. (A) PCA (2 components) followed by t-SNE. (B) t-SNE of the DA (250 nodes) hidd
indicate longer survival. (For interpretation of the references to color in this figure legedefinition in the original PheWAS publication, particularly for rare
phenotypes or phenotypes that do not directly correspond with a
billing code. In addition, several studies have found increased
genetic linkage via subtyping [15–19,44]. Li et al. [20] presented
a powerful example of EHR subtyping of patients with type 2 dia-
betes using a similar methodology, but they utilized Ayasdi, a com-
mercial, closed source topology data analysis software tool. Our
method is built on free, open source libraries that will continue
to be improved and our software is accessible for the research
community.
DA nodes and clusters of nodes provide composite variables
that may better approximate and represent the condition of the
subject. These additional phenotype targets may provide more
homogeneous targets for genotype associations. Beyond genotype
to phenotype association, these visualizations may also help clini-
cians to understand the level of heterogeneity for a specific disease
and to make treatment associations among sub-clusters of
patients. While further work is required to analyze the makeup
and meaning of the ALS survival clusters recognized by DAPS, they
suggest a helpful starting point for investigation.
Our work provides an important contribution but additional
analysis and challenges remain. The transition from simulated
data and relatively homogenous clinical trial data to diverse
multi-disease real world clinical data will likely require additional
steps. In addition, in our simulations we assume a preprocessing
step has already been performed to handle the compound
structure present in the EHR. This step is necessary to transform
categorical, free text, images and temporal data to suitable input
for the DA. The PRO-ACT ALS clinical trial data does not currently
include any free text or images. Raw EHR data will not be as
complete or clean as either clinical trial or simulated data.
Despite these challenges, autoencoders have been shown to
effectively denoise data [45,46], and may also be well suited to
noisy EHR-derived data.
Future work will focus on developing tools to examine and
interpret constructed phenotypes (hidden nodes) and clusters. In
addition, we will develop a framework for evaluating the
significance of constructed clusters for genotype to phenotypeen layer. All cluster coloring was determined by rank of days survived. Light colors
nd, the reader is referred to the web version of this article.)
B.K. Beaulieu-Jones, C.S. Greene / Journal of Biomedical Informatics 64 (2016) 168–178 177association. We anticipate high weights indicate important con-
tributors to node construction revealing relevant combinations of
input features. Finally we will construct a scheme for determining
optimal hyper parameter (i.e. hidden node count) selection.Conflict of interest
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